Medical/Pharmaceuticals Global News & Press Release Distribution

WuXi Biologics Obtains GMP Certification from UK MHRA for Commercial Manufacturing of an Ophthalmic Biologic

WUXI, China, Jan. 12, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that two of its manufacturing facilities in Wuxi –Drug Product Facility 5 (DP5) and Drug Product Packaging Center (DPPC) – have r...

2026-01-13 11:07 649

Abbisko Therapeutics Announces FDA Acceptance of the NDA for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor

SHANGHAI, Jan. 12, 2026 /PRNewswire/ -- 13 January 2026 (Beijing Time), Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) announcedtoday that the New Drug Application (NDA) for its novel, orally administered, highly selective, and potent small-molecule colony-...

2026-01-13 08:54 549

Abbisko Therapeutics Announces FDA Acceptance of the NDA for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor

SHANGHAI, Jan. 12, 2026 /PRNewswire/ -- 13 January 2026 (Beijing Time), Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) announcedtoday that the New Drug Application (NDA) for its novel, orally administered, highly selective, and potent small-molecule colony-...

2026-01-13 08:54 616

AbbVie and Trump Administration Reach Agreement to Improve Access and Affordability for Americans

* AbbVie will provide low prices in Medicaid, and expand affordable, direct-to-patient offerings for treatments used by millions of Americans through TrumpRx * AbbVie will commit $100 billion in U.S. research and development (R&D) and capital investments, including manufacturing, over the nex...

2026-01-13 07:30 300

Datasea Announces Major Acoustic Technology Advancements in Brain-Computer Interface Applications

Acoustic-Driven Technologies Poised to Support Embodied Intelligence and Health Robotics Applications in a Multi-Billion-Dollar Brain–Computer Interface Market BEIJING, Jan. 12, 2026 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), a technology company specializing in aco...

2026-01-12 22:30 441

Deepson Bio Receives Presidential Award at 2025 Korea Invention Patent Exhibition

Award highlights promise of ultrasound-based innovation in addressing unmet needs in dementia treatment SEOUL, South Korea, Jan. 12, 2026 /PRNewswire/ -- Deepson Bio Co., Ltd., a medical technology company focused on ultrasound-based approaches to dementia treatment, was honored with the Preside...

2026-01-12 22:00 474

Deepson Bio Receives Presidential Award at 2025 Korea Invention Patent Exhibition

LumiMind Wins SPEED AWARD at CES 2026 for Innovative Non-Invasive Sleep Technology With Real-Time EEG

LAS VEGAS, Jan. 12, 2026 /PRNewswire/ -- LumiMind, a next-generation neurotechnology company advancing non-invasive brain health solutions, today announced that it has won theSPEED AWARD at CES 2026 for its breakthrough consumer sleep technology,LumiSleep.

2026-01-12 22:00 487

LumiMind Wins SPEED AWARD at CES 2026 for Innovative Non-Invasive Sleep Technology With Real-Time EEG

Insilico Medicine Completes First Patient First Dose in BETHESDA: A Phase II Trial for Garutadustat (ISM5411), the Gut-restricted AI-driven PHD Inhibitor for the Treatment of Inflammatory Bowel Disease

CAMBRIDGE, Mass., Jan. 12, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico"), a clinical-stage, generative AI-driven drug discovery company, today announced the completion of first patient first dose in BETHESDA: a Phase IIa clinical trial of ISM5411 (NCT07265570

2026-01-12 21:30 381

WuXi Biologics Launches Industry-Leading Digital Twin Platform PatroLab™ Designed to Transform Bioprocessing and Manufacturing

SHANGHAI, Jan. 12, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the launch of PatroLabTM, a state-of-the-art digital twin platform designed to transform bioprocess development and manufactur...

2026-01-12 21:09 727

CARsgen and Dispatch Bio Announce Clinical Collaboration to Evaluate Flare Platform and Zevor-cel in Solid Tumors

SHANGHAI, PHILADELPHIA and SAN FRANCISCO, Jan. 12, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, and Dispatch Bio, a biotech company engineering a universal treatment across solid tumors leveragin...

2026-01-12 21:05 598

CARsgen and Dispatch Bio Announce Clinical Collaboration to Evaluate Flare Platform and Zevor-cel in Solid Tumors

Leadgene Biosolutions Expands Its Product Portfolio Following Strategic Integration, Advancing Early-Stage Mixing and Long-Term Metabolic Insight

TAIPEI, Jan. 12, 2026 /PRNewswire/ -- Leadgene Biosolutions today announces the expansion of its product portfolio following its strategic integration into Leadgene Biomedical. The expanded portfolio supports both early-stage cell line development and long-term metabolic research, enabling resear...

2026-01-12 21:00 533

Haisco Grants Global Rights of Innovative Drug HSK39004 to AirNexis in Deal Exceeding USD 1 Billion

HSK39004, a novel dual‑target therapy, aims to compete in the global COPD market, highlighting innovation and international capabilities BEIJING, Jan. 12, 2026 /PRNewswire/ -- On January 9, 2026, Haisco Pharmaceutical Group Co., Ltd. (Ticker Code: 002653) announced that it has entered into an ex...

2026-01-12 20:00 449

WuXi AppTec Issues Positive Profit Alert for the Full Year of 2025

SHANGHAI, Jan. 12, 2026 /PRNewswire/ -- WuXi AppTec (stock code: 603259.SH/2359.HK), a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), today issued a Positive Profit Alert for the full year of 2025, disclosing forecasts of key operational data...

2026-01-12 17:30 691

Formosa Pharmaceuticals Announces Licensing Agreement with Samil Pharmaceuticals, Co., Ltd, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery

TAIPEI, Jan. 12, 2026 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW) announced today that the company has entered into an exclusive licensing agreement with Samil Pharmaceuticals, Co., Ltd ("Samil", 000520.KS), for exclusive rights to the commercialization of clobetasol...

2026-01-12 16:00 525

Clover Initiates Phase 2 Clinical Trial for RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates

-- Phase 2 Initiation Strengthens Global First-in-Class Potential for Clover's Protein-Based RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates -- SHANGHAI, Jan. 12, 2026 /PRNewswire/ -- Clover Biopharmaceuticals, Ltd.  (Clover; HKEX: 02197), a global ...

2026-01-12 12:33 70

Zylox-Tonbridge Hosts Investor Open Day, Showcasing Innovation Pipeline and Global Growth Strategy

HANGZHOU, China, Jan. 11, 2026 /PRNewswire/ -- Zylox-Tonbridge Medical Technology Co., Ltd. (HKEX: 2190), a leading innovator in neurovascular and peripheral vascular interventional solutions, hosted its Investor Open Day at its Zhuhai Innovation Center, welcoming nearly 150 institutional investo...

2026-01-12 12:16 438

Nona Biosciences Enters into Collaboration Agreement with Link Cell Therapies to Advance CAR-T Cell Therapies

CAMBRIDGE, Mass., Jan. 9, 2026 /PRNewswire/ -- Nona Biosciences ("Nona"), a global biotechnology company advancing biologics discovery through innovative technology platforms, today announced that it has entered into a multi-target antibody discovery collaboration with Link Cell Therapies. This c...

2026-01-09 20:00 177

Innovent's Partner Ollin Biosciences Announces Positive Topline Data with Superior Outcomes from a Randomized Head-to-Head Study of IBI324 Compared to Faricimab (Vabysmo®) in Diabetic Macular Edema and Wet Age-Related Macular Degeneration

SAN FRANCISCO and SUZHOU, China, Jan. 8, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic...

2026-01-09 08:00 205

MediLink Has Signed an Additional Exclusive Licensing Agreement with Roche

SUZHOU, China, Jan. 8, 2026 /PRNewswire/ -- MediLink Therapeutics ("MediLink") today announced that it has entered into a new collaboration and exclusive licensing agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) for the development and commercialization of YL201, an investigational novel antib...

2026-01-09 08:00 148

Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End

SYDNEY, Jan. 8, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA) today announced that its Chief Executive Officer,John Friend, MD, will be in San Francisco next week to participate in meetings during the annual J.P. Morgan Healthcare Conference week (JPM Week). During the week, Kazia will ...

2026-01-08 22:00 551